(1) Clearly ours was an in vitro study designed to explore the molecular actions of neurodevelopmental toxins on methionine synthase, not an examination of the biodistribution of organomercurials. That said, the assertion that 'ethylmercury is unlikely to enter the brain at concentrations likely to be harmful' is wishful thinking and simply untrue. To the contrary, results presented at the recent 'Immunization Safety Review: Vaccines and Autism' at the Institutes of Medicine showed the brain-to-blood ratio in primates to be 5.1 for ethylmercury and 3.4 for methylmercury.
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The elimination half-life of ethylmercury was indeed shorter than that of methylmercury (18 vs 59 days for brain clearance). However, there is evidence that autistic children have a significantly impaired capacity to clear mercury, 2 due to lower levels of cysteine and glutathione, which probably accounts, at least in part, for their increased risk.
(2) SH-SY5Y human neuroblastoma cells are the most widely employed cultured human neuronal cell line, and they express a native population of D4 dopamine receptors, making them uniquely suitable for the study of neurodevelopmental toxins on D4 receptor-mediated phospholipid methylation. Others have previously described the ability of thimerosal to induce apoptosis in primary cultures of human cerebral cortical neurons. 3 We agree that the effects of neurodevelopmental toxins will depend on the timing of exposure. Thimerosal exposure in the first two postnatal years occurs during a period of exceptionally active synaptogenesis accompanied by the assembly of neuronal networks that are guided by attention. Impaired methylation during this period could have profound and long-lasting consequences for cognitive function. (4) Indeed, several other epidemiological studies did not find an association between levels of thimerosal exposure and autism rate, 4,5 although in some cases questions have been raised about the study design and potential investigator bias. 6 One study did find a significant association between the total level of thimerosal exposure at 3 and 7 months and language delay in one HMO population, but not another. 5 The inherent limitations of epidemiological studies to identify mechanistic factors suggests that studies focused on autistic subjects may be more fruitful in revealing risk factors and/or triggering agents than broad population-based approaches.
Finally, Offit and Golden express concern that parents of autistic children, who are 'desperate to find the cause or causes of the disease', may somehow be misled by our in vitro findings. To the contrary, recognition of thimerosal's potent inhibitory effect on PI3-kinase-dependent methylation pathways may allow better understanding of the causes and risk factors for autism. This is precisely the knowledge that parents are seeking and it is the appropriate role of scientific inquiry and scientific journals to provide such new information. Effectiveness of the vaccine program, with all its benefits, will ultimately be favored by public confidence that vaccines are as safely formulated as possible.
